Palmedo H, Grünwald F, Wagner U, Köhler S, Krebs D, Biersack H J
Department of Nuclear Medicine, University of Bonn, Germany.
Clin Nucl Med. 1998 Aug;23(8):501-4. doi: 10.1097/00003072-199808000-00001.
A patient with disseminated osseous metastases due to breast cancer reported multifocal pain. Because of persisting pain after a first cycle of chemotherapy, 1,295 MBq Re-186 HEDP was administered intravenously. Excellent pain relief was observed. Subsequently, the patient received further combined chemotherapy and Re-186 HEDP therapy and remained pain free. Tc-99m MDP bone imaging showed a significant regression of osseous metastases. It may be speculated that the combination of Re-186 HEDP and chemotherapy results in significantly increased palliation of metastatic bone disease.
一名因乳腺癌发生弥漫性骨转移的患者报告有多灶性疼痛。由于在第一个化疗周期后疼痛持续存在，静脉注射了1295MBq的铼-186 羟基亚乙基二膦酸盐（Re-186 HEDP）。观察到疼痛得到了显著缓解。随后，该患者接受了进一步的联合化疗和Re-186 HEDP治疗，并且一直没有疼痛。锝-99m亚甲基二膦酸盐（Tc-99m MDP）骨显像显示骨转移灶明显消退。可以推测，Re-186 HEDP与化疗联合使用可显著提高转移性骨病的缓解效果。
